DEXEMEL 4%

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

ICODEXTRIN SODIUM CHLORIDE PH.EUR. S(+) SODIUM LACTATE 960%W/W SOLUTION CALCIUM CHLORIDE DIHYDRATE MAGNESIUM CHLORIDE HEXAHYDRATE

Available from:

Innovata plc

Dosage:

40 Mg/Ml

Pharmaceutical form:

Solvent for Parenteral Use

Authorization date:

2001-07-27

Summary of Product characteristics

                                PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Dexemel 40g/litre Solvent for intraperitoneal use.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Theoretical osmolarity 278 (milliosmoles per litre).
Electrolyte solution content per 1000ml:
For excipients see section 6.1.
3 PHARMACEUTICAL FORM
Solvent for intraperitoneal use.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Dexemel is recommended as a vehicle for the administration via the peritoneum of medicinal products compatible with
the vehicle and shown to have been used safely and effectively by the intraperitoneal route.
See section 6.2.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
The Posology and technique applied depend on the pharmaco-kinetic attributes of the therapeutic agent which has been
dissolved in Dexemel and are individually decided by the responsible physician.
1 Litre (approximately 15 ml/kg) may be instilled into the peritoneal cavity thrice weekly via a subcutaneously
implanted port/catheter device.
2 Litres (approximately 30 ml/kg) may be instilled daily into the peritoneal cavity via a Tenckhoff catheter if drained
out immediately prior to a second instillation.
Each 1 litre contains:
Icodextrin
40.0
g
Sodium Chloride
5.4
g
S (+) Sodium Lactate (60%w/w solution)
4.5
g
Calcium Chloride
257.0
mg
Magnesium Chloride
51.0
mg
Sodium
133.0
mmol
Calcium
1.75
mmol
Magnesium
0.25
mmol
Chloride
96.0
mmol
Lactate
40.0
mmol
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 20/11/2007_
_CRN 2043438_
_page number: 1_
The dosage frequency of the therapeutic agent should be determined by its known pharmacokinetic attributes.
Peritoneal administration requires the use of a specific and adequate ambulatory drug delivery system, permitting the
conne
                                
                                Read the complete document
                                
                            

Search alerts related to this product

View documents history